One of the most active (by revenue) areas of cell therapy and tissue engineering is in the application of these technologies in orthopedics and spine surgery. It represents the single largest clinical area of sales of these products, driven by the well established tissue grafts business. Active areas include treatments in non-union fractures, cartilage repair, ligament repair, vertebral disc repair, and bone graft applications.
Below are the most recent full year shares of the orthopedic/spine market in cell therapy and tissue engineering.
* Others include Angiotech Pharmaceuticals, Inc., Biocomposites, Biocoral Inc., Biomet, Inc., BioMimetic Therapeutics, BioSyntech, BioTissue Technologies GmbH, co.don AG, ConMed Linvatec Biomaterials, Inc., Exactech, Inc., Fidia Advanced Biopolymers / Anika Therapeutics, Inc., Forticell Bioscience, Inc., Genzyme Biosurgery, Inion Ltd, ISTO Technologies Inc., Kensey Nash, organogenesis Inc., Orthovita, ReGen Biologics Inc., Serica Technologies, Inc. (Allergan), Smith & Nephew Ltd., SpineSmith, LP, Synovis Life Technologies, Inc., TEI Biosciences Inc., ThermoGenesis, Corp.
Source: MedMarket Diligence, LLC; Report #S520.